ATOS Stock — Atossa Therapeutics Inc.: Cash, EV, Pipeline

Share price

$2.22

Market cap

$22.2M

Cash

$26.1M

Enterprise value

-$3.9M

Balance sheet

Cash	$26.1M
Debt	$0.0M
Net cash	$26.1M
Enterprise value	-$3.9M
Basic shares	10.0M shares
Fully diluted shares	11.6M shares
Fully diluted market cap	$25.7M
Cash per share	$2.61

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ATOS daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 13, 2026 - Jan 24, 2027	(Z)-endoxifen	Phase 2	Breast Neoplasms; Invasive Breast Cancer; Estrogen-receptor-positive Breast Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

(Z)-endoxifen

Phase 2 · Active Modality: oral small-molecule selective estrogen receptor modulator/degrader

Target estrogen receptor (ER); PKCbeta1

Indications

ER+ breast cancer (neoadjuvant, DCIS, EVANGELINE) (Phase 2)
mammographic breast density reduction (Phase 2)
Duchenne muscular dystrophy (exploratory) (Phase 2)
McCune-Albright syndrome (exploratory) (Phase 2)

Catalysts

— Q3 2026
— H2 2026

Status note Lead candidate in four Phase 2 trials; no discontinuation disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	(Z)-endoxifen
Lead indication	Breast Neoplasms
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05607004	Phase 2	Active, not recruiting	Sponsor	ATOS	—	Breast Neoplasms; Invasive Breast Cancer; Estrogen-receptor-positive Breast Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Atossa Therapeutics, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

ATOS — Atossa Therapeutics Inc.